Sublingual NAD+ vs IV NAD+: An Honest Comparison

Short answer: For most people, sublingual strips are the NAD+ route that fits real life — needle-free, at home, in minutes, at a fraction of clinic prices. IV NAD+ offers maximum delivery certainty at clinic cost and clinic hours; oral precursors (NMN, NR) carry the deepest human trial file. Each route has a genuine strength.

Most articles comparing sublingual NAD+ vs IV are written by a clinic selling drips or a brand selling strips. We sell strips — so we'll do this properly: all three routes, honestly, including the oral precursors we don't sell. For background on the molecule itself, start with our NAD+ education hub. This article is about the "how."

What each route actually is

IV NAD+: the clinic route. NAD+ dissolved in a drip bag, delivered intravenously over a session that typically runs one to several hours, with an appointment, a needle, and supervision. Reported clinic pricing commonly lands in the several-hundred-dollars-per-session range — treat any specific number as reported pricing that varies by clinic and region.

Sublingual strips: the at-home route. A thin dissolving film placed under the tongue, where thin, well-vascularized tissue lets suitable compounds pass toward circulation while skipping digestion. Minutes, at home, no needles, no appointments. Our Energy NAD+ strip carries a labeled 100 mg of NAD+ per strip.

Oral precursors: NMN and NR capsules. The third route isn't NAD+ at all — it's the smaller building blocks your body absorbs and converts into NAD+ itself. We don't sell them, and we include them anyway, because an honest comparison can't skip the route with the most human data behind it.

Why the strip format has real momentum

Here's the part older comparison articles miss: sublingual NAD+ research is genuinely moving. A company developing a sublingual NAD+ wafer (iX Biopharma's SL-NAD+) reported a rat pharmacokinetic study showing peak blood NAD+ roughly doubling within 10 minutes of sublingual dosing [preclinical evidence], followed by a small company-sponsored human pilot in nine healthy adults reporting average whole-blood NAD+ increases of +59% at two weeks and +76% at six weeks versus baseline — open-label and uncontrolled, so early signal rather than proof, but exactly the kind of work that turns a plausible route into a studied one [brand claim — unverified].

The regulatory picture is loosening in parallel, and that's documented: after FDA excluded NMN from the dietary-supplement definition in 2022, the agency reversed course in late 2025 and formally reinstated NMN's ingredient status. The rules around NAD-pathway ingredients are actively being re-examined, and the direction of travel has been toward more lawful access, not less. Meanwhile the precursor evidence keeps stacking: NR raised blood NAD+ in the landmark Trammell et al. human trial (2016), and a 2026 head-to-head (Christen et al., Nature Metabolism) found both NMN and NR roughly doubled blood NAD+ at 1,000 mg/day [published human data]. The NAD+ category's science is growing in every direction — and the strip sits inside that momentum.

The honest context, once

Plainly, because you deserve the whole canvas: IV is the only route with inherent 100% delivery certainty — the molecule goes straight into circulation. No published human pharmacokinetic study has yet measured intact NAD+ absorption from a dissolving strip specifically, and intact NAD+ is a large, charged molecule (~663 Da) — the reason the early sublingual data above matters so much, and the reason we won't quote you an absorption percentage as fact. If guaranteed bloodstream delivery is your single top criterion and cost is no object, IV wins that one criterion. Everything else is a different conversation.

The decision factors that actually matter

Run the cost math honestly: even one monthly IV session at reported clinic prices can exceed months of strips. Consistency is the variable that decides most wellness outcomes — and the format that wins on consistency is the one that lives in your morning routine, not behind a scheduling desk.

The verdict: which one wins for you

IV wins for the reader who wants maximum delivery certainty, genuinely doesn't mind needles, appointments, or clinic pricing, and prefers a supervised setting. That's a legitimate choice.

Precursors win for the reader whose deciding factor is published human biomarker data today, in capsule form.

The strip wins for everyone else — and that's most people: you want needle-free NAD+ support you can sustain daily, at a cost that doesn't require a financing plan, in a format whose early research is moving in the right direction. For the reader deciding today, the strip is the winner on convenience, cost, and consistency — the three factors that determine whether any routine survives past week two.

If cellular energy support is your broader interest, it's worth knowing about MOTS-c, a mitochondrial-derived peptide — the active in our BOOST MOTS-c strips, now available at open checkout.

The bottom line

IV has certainty, precursors have the capsule trials, and strips have the life-fit — plus a research trajectory pointed the right way. For the reader who wants NAD+ support that survives a busy week and a real budget, the strip is the format that wins where it counts.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.